3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Transitional Cell
14
Urinary Bladder Neoplasms
11
Breast Neoplasms
11
Neoplasm Metastasis
10
Carcinoma, Renal Cell
8
Carcinoma, Merkel Cell
8
Neoplasms
7
Colorectal Neoplasms
7
Head and Neck Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Neuroendocrine Tumors
4
Leukemia, Myeloid, Acute
4
Urethral Neoplasms
3
Ureteral Neoplasms
3
Skin Neoplasms
3
Prostatic Neoplasms
3
Glioblastoma
3
Endometrial Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Neuroendocrine
3
Carcinoma, Hepatocellular
3
Small Cell Lung Carcinoma
2
Sarcoma
2
Penile Neoplasms
2
Pancreatic Neoplasms
2
Non-Muscle Invasive Bladder Neoplasms
2
Neoplasm, Residual
2
Mesothelioma, Malignant
2
Interventions
Nivolumab
3
pembrolizumab
2
durvalumab
2
tremelimumab
1
relatlimab
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
fludarabine phosphate
1
fludarabine
1
bintrafusp alfa protein, human
1
avelumab
1
Therapeutics
1
Temozolomide
1
Surgical Procedures, Operative
1
Specimen Handling
1
Oxaliplatin
1
Neoadjuvant Therapy
1
Ipilimumab
1
Injections
1
Immunoglobulin G
1
High-Throughput Nucleotide Sequencing
1
Educational Status
1
Drug Therapy
1
Disulfides
1
Cyclophosphamide
1
Chemotherapy, Adjuvant
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Microsatellite Instability
×
avelumab
×
Clear all
NCT03827044
2022-10-07
POLEM
Royal Marsden NHS Foundation Trust
Phase 3
Terminated
30 enrolled